BiTAC TCEs
T-cell-engaging (TCE) bispecific molecules represent a significant share of all bispecific therapies currently in development. T cell engagers target and activate cytotoxic T-cells to eliminate cancer cells via signaling of the CD3 surface receptor, while also binding to a second target protein on tumor cells.
While highly effective in some indications, side effects and unfavorable product characteristics continue to limit their widespread use. Especially on-target but off-tumor side effects triggering the killing of healthy cells remain a huge challenge.
Evolution of cancer therapies towards potent target specific-drugs
ADCs improve the therapeutic window by combining cytotoxic drugs with antibody targeting
BiTAC TCE precursors
VERAXA’s BiTAC version of a T cell engager is split into two complimentary parts, the BiTAC precursors. In their isolated form, the tumor-binding capability of each BiTAC precursor remains intact, while the CD3 binding motif is inactivated. This built-in safety feature is the key to reducing off-tumor toxicity.
Reducing off-target toxicity
Conventional bispecific TCEs fail in 80% of cases due to toxicity and the resulting lack of efficacy. On-target, off-tumor effects cause harmful side effects when target antigens are present on healthy cells.
Addressing two different targets with BiTACs in a combinatorial manner provides the basis for a much more specific interaction with the tumor cells, as unwanted T-cell recruitment via the CD3 binding domain is avoided.
Extending the therapeutic window
BiTAC TCEs feature a dual-targeting approach, enabling a more selective attack on cancer cells. Once both BiTAC TCE precursors bind to their respective target molecule, the CD3-binding domain is established and activated.
Restricting the cytotoxic T cell activity to the cancer cell with this “AND”-gated strategy build the basis to enable higher doses and widen the therapeutic window.
Functional antibody screening
Our proprietary microfluidic platform combines single-cell analysis with droplet-based microfluidic sorting to identify functional antibodies against a broad spectrum of targets.
Learn moreADC technology
Our bioengineering technology allows to position specific conjugation sites anywhere in the antibody. Our highly efficient click chemistry is then used to conjugate our payloads at these sites yielding efficacious, uniform and safe ADCs.
Learn more